Adults who continued to eat pork while participating in a 6-month digital weight management program lost a clinically significant 5.3% of starting body weight and improved their overall diet quality scores by 4.3 points. This study challenges the notion that pork is automatically off-limits within a healthier eating plan.
SourceNational Pork Board·JournalNutrition and Diabetes·TypeRandomized controlled/clinical trial·DateAug 18, 2026
A study by Rutgers researchers found that waist circumference measures nearly as accurately as a new obesity definition incorporating multiple body measurements, identifying potential health risks earlier. Waist measurement can provide a practical tool for clinicians and patients to detect unhealthy amounts of body fat.
SourceRutgers University·JournalJAMA Network Open·TypeData/statistical analysis·DateAug 14, 2026
A case-control study found that patients with overweight or obesity at diagnosis had better survival rates than those with normal weight. However, the apparent advantage was largely due to prediagnostic weight loss associated with cancer, and should not be taken as evidence for weight gain in healthy individuals.
SourceJAMA Network·JournalJAMA Network Open·DateAug 14, 2026
Researchers reviewed grant data from 2015-2022, supporting investment in a strong evidence base for obesity and cancer research. Key areas of focus include obesity's impact on cancer treatment and survivorship, as well as disparities in cancer outcomes.
SourceJAMA Network·JournalJAMA Network Open·DateAug 12, 2026
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
A cohort study investigates the association between bariatric surgery and preoperative use of GLP-1 receptor agonists. The results show a significant positive correlation between preoperative GLP-1 RA use and weight loss outcomes after surgery.
A new study published in JACC suggests that waist circumference and waist-to-hip ratio provide critical information about cardiovascular risk, even among people with a normal BMI. Individuals with elevated central adiposity were associated with higher risks for most outcomes, regardless of their weight status.
SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·DateAug 11, 2026
A hybrid lifestyle program showed potential benefits for cardiometabolic health among adherent participants with obesity, but failed to achieve significant weight loss. The study suggests further investigation into the program's effects on metabolic health.
SourceJAMA Network·JournalJAMA Network Open·DateAug 11, 2026
Tirzepatide has been shown to reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes and obesity. The study found a relative risk reduction of about one-third, corresponding to a 36% reduced risk of infection-related hospitalization.
SourceTechnical University of Munich (TUM)·JournalThe BMJ·TypeData/statistical analysis·DateAug 6, 2026
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A low-fat vegan diet reduces dietary energy density by 30%, enabling participants to eat satisfying amounts of food while taking in fewer calories and losing weight. This approach allows for greater flexibility and sustainability in weight management, focusing on the composition of the diet rather than calorie restriction.
SourcePhysicians Committee for Responsible Medicine·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateAug 6, 2026
Adults with type 2 diabetes have a high risk of fragility fractures, but new research found GLP-1 receptor agonists reduce this risk by 21% compared to DPP-4 inhibitors. The largest reductions occurred in hip, femur, and spine fractures.
SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·TypeObservational study·DateAug 4, 2026
Researchers are developing a new platform for obesity drug discovery using human-induced pluripotent stem cell-derived brain organoid models. They will test thousands of potential drug compounds on specialized brain cells to identify those that activate the protein adenylate cyclase 3 (ADCY3), a key regulator of appetite and body weight.
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
Researchers at the University of Cambridge solved the puzzle of why stimulating and blocking a specific 'switch' in the brain can help people lose weight. By targeting distinct regions of the brain, they found that GIPR agonists suppress appetite, while GIPR antagonists boost weight loss by releasing a 'brake'.
SourceUniversity of Cambridge·JournalNature Metabolism·TypeExperimental study·DateJul 24, 2026
Researchers identified endotrophin as a biological marker that rises and falls with changes in body fat, reflecting changes in metabolic health. The study suggests endotrophin could serve as a valuable biomarker and therapeutic target for reducing obesity-related health risks.
SourcePennington Biomedical Research Center·JournalMetabolism·DateJul 23, 2026
Researchers from Pennington Biomedical will present findings on organoid models, GLP-1 therapies, and early-life nutrition. The center's broad research portfolio is represented at the annual meeting of the American Society for Nutrition.
SourcePennington Biomedical Research Center·DateJul 23, 2026
Researchers developed a handheld breath detector that measures acetone levels with laboratory-level accuracy in 90 seconds. The device tracks changes in fat metabolism during various scenarios, including exercise and fasting, providing insights for clinicians to personalize treatments.
SourceCell Press·JournalDevice·TypeExperimental study·DateJul 22, 2026
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers found that semaglutide treatment continued to reduce calorie intake even as participants felt hunger sensations return, contributing to sustained weight loss. Participants who took semaglutide lost an average of 15.1% of their initial body weight after 60 weeks, compared to 3.4% for placebo recipients.
SourceUniversity of Pennsylvania School of Medicine·JournalAmerican Journal of Clinical Nutrition·DateJul 21, 2026
Repeatedly losing and gaining weight accelerates muscle loss in middle-aged people, as found in new UC San Francisco research. The study analyzed MRI scans of 1,433 participants and found that those with fluctuating weights lost nearly four times as much thigh muscle over four years.
SourceUniversity of California - San Francisco·JournalRadiology·DateJul 21, 2026
Researchers urge caution on GLP-1 insurance coverage due to massive budget impact and limited data supporting long-term savings. Compounded versions of the medication can be unsafe, and patients require comprehensive support to achieve weight loss and disease prevention.
SourceUniversity of Mississippi·JournalJournal of Managed Care & Specialty Pharmacy·DateJul 20, 2026
The GLP-1 RA market experienced a surge in demand following the semaglutide and tirzepatide shortages. Compounded GLP-1 RAs sourced from unlicensed facilities pose clinical and regulatory challenges.
SourceJAMA Network·JournalJAMA Health Forum·DateJul 17, 2026
A Northwestern University study found that average total payments per user for GLP-1 drugs more than doubled from 2017 to 2022. This raises concerns about the long-term affordability of these medications, which may be taken by patients for years or decades.
SourceNorthwestern University·JournalJournal of the American Heart Association·DateJul 16, 2026
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
A systematic review and meta-analysis found that weight loss drugs can reduce key symptoms of binge eating disorder, including binge eating episodes, loss-of-control eating, and emotional eating. The study suggests that these medications could be an important part of treatment plans for people with binge eating disorder.
SourceUniversity College London·JournalEClinicalMedicine·TypeMeta-analysis·DateJul 15, 2026
After Medicare expanded coverage for Wegovy to prevent heart complications in obese patients with heart disease, prescription fills jumped sharply. However, a significant fraction of eligible beneficiaries still did not receive the treatment.
SourceUniversity of Southern California·DateJul 9, 2026
Researchers have found that GLP-1 agonists can normalize genetic pathways involved in pulmonary fibrosis, a lung disease associated with Long COVID. The treatment has shown promise in reducing the risk of fibrous buildup, suggesting potential benefits for people with type 2 diabetes and severe COVID-19 symptoms.
SourceAmerican Society for Microbiology·JournalJournal of Virology·DateJul 9, 2026
A new study from the University of Copenhagen shows that exercise plays a crucial role in improving cardiovascular health even after significant weight loss. Participants who exercised developed healthier blood vessels and lower inflammation compared to those who relied on medication alone.
SourceUniversity of Copenhagen·JournalNature Metabolism·DateJul 8, 2026
The study found a 37% increase in obesity and a two-fold increase in severe obesity among both adults and youth over 20 years. Obesity rates have major implications for cardiovascular disease and mortality, highlighting the need for targeted initiatives to address the rising epidemic.
SourceAmerican Heart Association·JournalCirculation·DateJul 7, 2026
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A cross-sectional study found significant increases in glucagon-like peptide-1 (GLP-1) per-patient days supplied in employer plans from 2021 to 2024, driven by higher growth in weight loss coverage. This could signal a growing financial burden on patients and payers as drug costs increase over time.
SourceJAMA Network·JournalJAMA Health Forum·DateJun 26, 2026
A review of research on repeated weight loss and regain suggests that yo-yo dieting is not necessarily as harmful as often portrayed. The benefits of weight loss can outweigh the potential risks of later weight regain, with several large studies showing that obesity itself is a primary driver of metabolic disease risk.
SourceUniversity of Copenhagen·JournalThe Lancet Diabetes & Endocrinology·DateJun 24, 2026
Researchers analyzed TikTok videos discussing food noise, finding it's a relentless preoccupation with eating that affects daily activities. The study aims to bring evidence to differentiate between scientific claims and marketing purposes.
SourcePenn State·JournalNutrition and Diabetes·TypeContent analysis·DateJun 23, 2026
The AGA commentary updates the POWER framework to reflect major advances in obesity care, including effective anti-obesity medications and bariatric surgery. Gastroenterologists play a crucial role in obesity management, caring for patients with related conditions.
SourceAmerican Gastroenterological Association·JournalGastroenterology·DateJun 17, 2026
New research found that GLP-1 RA users showed weaker associations between impulsivity and violent crime, suggesting these medications may lessen risk factors. The study analyzed data from a US survey of adults who used GLP-1 medications.
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
Researchers at Rutgers University link GLP-1 medication use to reduced violent behavior, finding a substantial weakening of the relationship between impulsivity and aggression among users compared to non-users. The study suggests these medications may work like cognitive behavioral therapy, reducing impulsive actions.
SourceRutgers University·JournalCriminology·TypeSurvey·DateJun 17, 2026
A new study found that patients taking weight-loss drug tirzepatide experienced significantly more weight loss than those on semaglutide, with nearly twice as many high responders. Additionally, tirzepatide showed fewer gastrointestinal side effects and more significant weight loss in women and white patients.
A recent study found that women and individuals with minimal motivation to lose weight experienced greater weight loss on tirzepatide. The research also identified baseline clinical, demographic, and behavioral variables associated with weight loss trajectories over 12 months.
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
A study found that tirzepatide significantly increases brown adipose tissue activity and volume in premenopausal women with obesity. The medication also shows potential signs of converting white subcutaneous fat into more metabolically active 'beige' fat.
The NOVO EXPENDITURE trial investigates the effects of a hormone-based treatment on weight loss compared to a reduced-calorie diet. Participants will undergo extensive physiological testing, including metabolic chamber sessions and regular weigh-ins, to assess the treatment's impact on energy use and body weight.
SourcePennington Biomedical Research Center·DateJun 15, 2026
The American College of Physicians recommends semaglutide and tirzepatide as first-line treatments for nonpregnant adults with obesity, while recommending lifestyle modifications including improved nutrition and physical activity. The guideline also emphasizes discussing benefits, harms, costs, and contraindications with patients.
SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateJun 15, 2026
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
A study presented at ENDO 2026 found semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications. The results suggest that semaglutide may have beneficial effects on bone health in people with type 2 diabetes.
A study found that nearly 4 in 10 patients stopped GLP-1 medication within the first year and nearly two-thirds restarted therapy within two years. The researchers also identified sociodemographic, clinical, and provider-level predictors of discontinuation, including Medicaid or Medicare status, Black patients, and side effects.
A study found that adults taking GLP-1 receptor agonist medications experienced significant decreases in daily step counts and moderate-to-vigorous physical activity, highlighting the need for targeted interventions to promote exercise alongside obesity treatment.
A reduction in visceral fat is associated with better cardiometabolic health and lower future type 2 diabetes risk, even when body weight is fully regained. Visceral fat loss achieves a significant protective effect against systemic aging and metabolic decay long after a diet ends.
SourceBen-Gurion University of the Negev·JournalCirculation·TypeRandomized controlled/clinical trial·DateJun 10, 2026
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
A new study published in Menopause journal found that replacing animal protein with plant-based sources like soybeans, beans, and grains leads to significant weight loss in postmenopausal women. The study's lead author suggests that the quality of protein, not just quantity, plays a key role in weight regulation and metabolic health.
SourcePhysicians Committee for Responsible Medicine·JournalMenopause·TypeRandomized controlled/clinical trial·DateJun 9, 2026
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateJun 7, 2026
Mazdutide, a GLP-1 receptor dual agonist, provides clinically meaningful weight reduction in Chinese adults with obesity. However, gastrointestinal adverse reactions are more common among those taking the drug compared to placebo.
Adults with both obesity and an autoimmune disease who took a GLP-1-based medication had fewer emergency department visits and lower mortality rates compared to those not taking the medication. The study analyzed data from over 26,000 adults treated in the OneFlorida+ network between 2014 and 2024.
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
Researchers found that a compound already in clinical trials for age-related muscle loss may mitigate the negative effects of GLP-1 on muscle health. In young adult mice treated with semaglutide, PGDHi enhanced muscle regeneration and recovery after injury, restoring strength without undermining fat loss.
SourceStanford Medicine·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJun 2, 2026
Weight loss after bariatric surgery is associated with better ability to cope with daily household tasks such as cleaning and grocery shopping. The study also found that maintaining weight loss for long periods results in improved functionality and independence. Patients who regained lost weight experienced poorer outcomes over time.
SourceUniversity of Gothenburg·JournalBMC Medicine·TypeObservational study·DateJun 1, 2026
Researchers at NIH have discovered key intracellular signaling processes involved in the weight-loss effects of semaglutide, a GLP-1 drug. The findings may help extend treatment duration and reduce plateaus experienced by patients.
SourceNIH/Office of the Director·JournalNature Metabolism·DateMay 22, 2026
A low-calorie diet and behavioral support program significantly reduced weight in older patients with overweight and persistent atrial fibrillation at 8 months. The study found no safety concerns or impact on atrial fibrillation symptoms, cardiac remodeling, or need for further rhythm control interventions.
A comparative study found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide. Patients undergoing ESG achieved a mean total body weight loss of 12.7%, compared to 8.7% in those receiving semaglutide.
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
A new study published at the European Congress on Obesity found that participants who underwent rapid weight loss lost significantly more weight than those who followed a gradual weight loss plan. After one year, the rapid weight loss group had achieved clinically meaningful weight loss and maintained it better than the gradual weight ...
SourceEuropean Association for the Study of Obesity·DateMay 14, 2026
A study found a significant decrease in metabolic bariatric surgery utilization between 2022 and 2024, with a 34.1% drop, while glucagon-like peptide-1 (GLP-1) use increased by 140.4% during the same period. This trend may continue due to growing prescribing of GLP-1s.
A systematic review found that obesity surgeries resulted in a higher proportion of fat-free mass loss compared to diet and exercise interventions. Incretin-based obesity drugs also led to greater fat-free mass loss than traditional weight loss methods.
SourceEuropean Association for the Study of Obesity·DateMay 13, 2026
A new study suggests that GLP-1 receptor agonists and GIP/GLP-1 receptor agonists can lead to substantial fat loss while preserving skeletal muscle mass in relative terms. The study found that muscle mass remained stable over time when accounting for changes in fat mass.
SourceEuropean Association for the Study of Obesity·DateMay 13, 2026
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
Research by Dr. Hanim Diktas at Pennington Biomedical Research Center shows that combining GLP-1 receptor agonists with behavioral intervention leads to a greater reduction in 'food noise', a persistent thought about food disrupting daily life and healthy behaviors. The study found significant decreases in food noise for participants u...
SourcePennington Biomedical Research Center·TypeObservational study·DateMay 12, 2026
Patients on tirzepatide at maximum dose have seven times higher odds of maintaining weight loss compared to those who stop treatment. Those on the lower 5mg dose have four times higher odds, according to a new study published in The Lancet.
SourceEuropean Association for the Study of Obesity·JournalThe Lancet·DateMay 12, 2026
New research finds that participants in the ATTAIN-MAINTAIN trial maintained a significant percentage of weight loss when switched from injectable tirzepatide or semaglutide to daily oral orforglipron treatment. The study shows that nearly all weight loss achieved on injectable therapies can be maintained by switching to oral therapies.
SourceEuropean Association for the Study of Obesity·JournalNature Medicine·DateMay 12, 2026
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
SourceUniversity of California - Riverside·JournalThe Journal of Physiology·TypeExperimental study·DateMay 11, 2026
A retrospective cohort study examining over 840,000 breast cancer patients found a potential link between GLP-1 RA use and improved outcomes among obese or diabetic patients. GLP-1 RAs were associated with lower risk of death and recurrence over a 10-year follow-up period.
SourceVirginia Commonwealth University·JournalJAMA Network Open·DateMay 11, 2026
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
SourceEuropean Association for the Study of Obesity·DateMay 10, 2026
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
SourceEuropean Association for the Study of Obesity·DateMay 10, 2026